Levetiracetam Tablet, Film Coated
Product Images NDC 71335-2098

10 FDA label images from Bryant Ranch Prepack · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 71335-2098). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Fdc77d21 Ac52 4c9e B53f 43681e769687 01)

Figure 1 (Fdc77d21 Ac52 4c9e B53f 43681e769687 01)
A formula showing the calculation of total daily dose in mL/day for Levetiracetam as a function of daily dose in mg/kg/day and patient weight in kg divided by a concentration of 100 mg/mL.*
FDA Label Image

Figure 2 (Fdc77d21 Ac52 4c9e B53f 43681e769687 02)

Figure 2 (Fdc77d21 Ac52 4c9e B53f 43681e769687 02)
A text panel showing formulas for calculating creatinine clearance (CLcr), including adjustments for age, weight, serum creatinine levels, sex, and body surface area (BSA). The formulas specify factors for female patients and normalization by body surface area in mL/min/1.73m² units.*
FDA Label Image

Structure (Fdc77d21 Ac52 4c9e B53f 43681e769687 03)

Structure (Fdc77d21 Ac52 4c9e B53f 43681e769687 03)
Chemical structure diagram of Levetiracetam, showing its molecular framework with a pyrrolidone ring and functional groups attached, consistent with its identity as the active ingredient in the product.*
FDA Label Image

Figure 4 (Fdc77d21 Ac52 4c9e B53f 43681e769687 04)

Figure 4 (Fdc77d21 Ac52 4c9e B53f 43681e769687 04)
A bar graph comparing the percentage of patients for three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The y-axis represents the percentage of patients (0% to 45%), showing 7.4% for Placebo, 37.1% for Levetiracetam 1000 mg/day, and 39.6% for Levetiracetam 3000 mg/day. Sample sizes (N) are indicated below each group.*
FDA Label Image

Figure 5 (Fdc77d21 Ac52 4c9e B53f 43681e769687 05)

Figure 5 (Fdc77d21 Ac52 4c9e B53f 43681e769687 05)
A bar chart comparing the percentage of patients across three groups: placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. The chart shows increasing patient percentages from placebo to higher doses of Levetiracetam.*
FDA Label Image

Figure 6 (Fdc77d21 Ac52 4c9e B53f 43681e769687 06)

Figure 6 (Fdc77d21 Ac52 4c9e B53f 43681e769687 06)
A vertical bar chart comparing the percentage of patients between two groups: Placebo (N=104) and Levetiracetam 3000 mg/day (N=180). The placebo group has a value of 14.4%, and the Levetiracetam group has a higher value of 39.4%, with an asterisk above the Levetiracetam bar indicating statistical significance.*
FDA Label Image

Figure 7 (Fdc77d21 Ac52 4c9e B53f 43681e769687 07)

Figure 7 (Fdc77d21 Ac52 4c9e B53f 43681e769687 07)
A bar chart comparing the percentage of patients between two groups: Placebo (N=97) with 19.6% and Levetiracetam (N=101) with 44.6%. The y-axis represents the percentage of patients, the x-axis shows the treatment groups, and a star symbol is displayed above the Levetiracetam bar.*
FDA Label Image

Figure 8 (Fdc77d21 Ac52 4c9e B53f 43681e769687 08)

Figure 8 (Fdc77d21 Ac52 4c9e B53f 43681e769687 08)
A bar chart comparing the percentage of patients between two groups: Placebo (N=51) and Levetiracetam (N=58). The y-axis represents the percentage of patients, with the Placebo group at 19.6% and the Levetiracetam group at 43.1%. An asterisk is marked within the Levetiracetam bar, indicating statistical significance or emphasis.*
FDA Label Image

Figure 9 (Fdc77d21 Ac52 4c9e B53f 43681e769687 09)

Figure 9 (Fdc77d21 Ac52 4c9e B53f 43681e769687 09)
A bar graph comparing the percentage of patients between placebo and Levetiracetam groups. The placebo group (N=84) shows 45.2% of patients, while the Levetiracetam group (N=79) shows 72.2%, with an asterisk marking the Levetiracetam bar, indicating statistical significance.*
FDA Label Image

Label (Lbl713352098)

Label (Lbl713352098)
Label for Levetiracetam 750 mg tablet by Bryant Ranch Prepack, comparing to Keppra 750 mg tablet by Lupin Limited. The label indicates a package count of 30 tablets with storage instructions at 20°-25°C (68°-77°F), a lot number 1523487, and the NDC 71335-2098. It includes a barcode and a warning to keep drugs out of reach of children.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.